American Society of Hirudotherapy

Bivalirudin Anticoagulation for a Pediatric Patient with Heparin-Induced Thrombocytopenia and Thrombosis Requiring Cardiopulmonary Bypass for Ventricular Assist Device Placement

Case report published in J Extra Corpor Technol (2016)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Case reportDrug DevelopmentClinical LiteratureFaella KH et al. · The journal of extra-corporeal technology, 2016

Abstract

The direct thrombin inhibitor bivalirudin is an option for anticoagulation in patients with heparin induced thrombocytopenia (HIT) requiring cardiopulmonary bypass (CPB). There are a limited number of reports of pediatric patients in which bivalirudin has been used for anticoagulation for CPB. We present the case of an 11 year old male with acute onset heart failure secondary to idiopathic dilated cardiomyopathy that developed heparin induced thrombocytopenia with thrombosis (HITT). The patient was anticoagulated in the operating room with bivalirudin and placed on CPB for insertion of a HeartWare(®) Ventricular Assist Device (Heartware(®)). Modified techniques were utilized. This included use of the Terumo CDI 500 (Terumo Cardiovascular Systems, Inc.) in-line blood gas monitor which contains a heparin coated arterial shunt sensor. We flushed this sensor with buffered saline preoperatively and noted no significant decrease in platelet count postoperatively. The patient was successfully placed on the ventricular assist device and was subsequently listed for heart transplantation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAnticoagulantsCardiomyopathy, DilatedCardiopulmonary BypassChildHeart FailureHeart TransplantationHeart-Assist DevicesHeparinHirudinsHumansMalePeptide FragmentsRecombinant ProteinsThrombocytopeniaThrombosis

Summary

An 11-year-old boy with idiopathic dilated cardiomyopathy who developed heparin-induced thrombocytopenia with thrombosis was anticoagulated with bivalirudin for cardiopulmonary bypass during HeartWare ventricular assist device insertion, using modified techniques including a buffered saline sensor flush.

Why This Matters for Hirudotherapy

This case report describes an 11-year-old boy with idiopathic dilated cardiomyopathy who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was anticoagulated with bivalirudin during cardiopulmonary bypass for HeartWare VAD insertion. The abstract notes modified techniques, including flushing a heparin-coated arterial sensor with buffered saline, with no significant postoperative platelet drop, and successful device placement with subsequent transplant listing. As a single case, the findings are not generalizable, and the abstract notes the limited number of pediatric reports in this area. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Faella KH, Whiting D, Fynn-Thompson F, Matte GS. Bivalirudin Anticoagulation for a Pediatric Patient with Heparin-Induced Thrombocytopenia and Thrombosis Requiring Cardiopulmonary Bypass for Ventricular Assist Device Placement. J Extra Corpor Technol. 2016;48(1):39-42. PMID: 27134308

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.